Common Contracts
1 similar null contracts
Evgen Pharma plcOctober 11th, 2022
• $0.5m upfront, $0.5m on completion of the, already fully financed, Evgen‐sponsored human volunteer Phase 1 study (anticipated during Q2 2023). Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double‐digit range in all scenarios, including on‐licensing by Stalicla and use of SFX‐01 in further licensed indications.
